Atopic Dermatitis (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Atopic dermatitis (AD) is a chronic inflammatory skin condition that typically begins in early childhood, causing age-specific skin problems, dryness, and severe itching. This condition significantly impacts the quality of life and makes patients more prone to allergic diseases. Numerous studies have linked AD during infancy to the later development of asthma, allergic rhinitis, and food allergies. About 80% of AD patients experience one or both of these conditions. Additionally, 35% of children with AD have food allergies, and they are more likely to suffer from skin infections and keratoconjunctivitis compared to the general population. Common chronic comorbidities in children with AD include asthma, psychosocial disorders, visual impairment, limb anomalies, and developmental issues. These comorbidities are more prevalent in those with AD. This group's most frequent acute conditions are upper respiratory tract infections, otitis media, conjunctivitis, and pharyngitis.
·
Thelansis indicates that globally, AD affects
15%–20% of children and 1%–3% of adults. The prevalence of AD is increasing
worldwide and varies by geographic location, with higher rates in
industrialized, high-income countries compared to agriculture-based, low-income
regions.
Thelansis’s
“Atopic Dermatitis (AD) Market Outlook, Epidemiology, Competitive Landscape,
and Market Forecast Report – 2023 To 2033" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Atopic
Dermatitis (AD) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Atopic Dermatitis
(AD) across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Atopic
Dermatitis (AD) Market Forecast Patient Based Forecast Model (MS.
Excel Based Automated Dashboard), which Data Inputs with sourcing, Market
Event, and Product Event, Country specific Forecast Model, Market uptake and
patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and
pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Atopic
Dermatitis (AD), Atopic Dermatitis (AD) market
outlook, Atopic Dermatitis (AD) competitive
landscape, Atopic Dermatitis (AD) market
forecast, Thelansis, Primary market research, KOL insights, Competitive
Intelligence (CI)
Comments
Post a Comment